GlassScriptPhysician profile
Peter Joseph Valastro, JR.
NPI 1811529415
$4,884.30
in general payments reported to CMS, 2019-2025
19 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $854 · 2023: $1,239 · 2024: $1,118 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,669.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $940.80 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $910.59 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $572.16 | 2022-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $369.20 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $335.38 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $282.19 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $278.19 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $244.19 | 2021-2025 | Ingrezza |
| Corium, LLC | $231.75 | 2023-2025 | Azstarys |
| Alkermes, INC. | $173.01 | 2021-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $151.48 | 2021-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $83.85 | 2022 | |
| Idorsia Pharmaceuticals US INC | $66.30 | 2023-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $63.81 | 2024-2025 | Austedo Xr, Uzedy |
| Novo Nordisk INC | $55.07 | 2025 | Wegovy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $48.01 | 2023-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $36.57 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $26.25 | 2024 | Cobenfy |
| Currax Pharmaceuticals LLC | $15.50 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Valastro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.